BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 26121913)

  • 1. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study.
    Bertoli HK; Thomsen LT; Iftner T; Dehlendorff C; Kjær SK
    Gynecol Oncol; 2020 May; 157(2):456-462. PubMed ID: 32008794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and Type-Distribution of Human Papillomavirus in Vulva and Vaginal Abnormal Cytology Lesions and Cancer Tissues from Thai Women.
    Ngamkham J; Boonmark K; Phansri T
    Asian Pac J Cancer Prev; 2016; 17(3):1129-34. PubMed ID: 27039737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Lindquist S; Frederiksen K; Petersen LK; Kjær SK
    Int J Cancer; 2024 Jul; 155(1):61-70. PubMed ID: 38418719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
    Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
    PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
    Smith JS; Backes DM; Hoots BE; Kurman RJ; Pimenta JM
    Obstet Gynecol; 2009 Apr; 113(4):917-924. PubMed ID: 19305339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile.
    Hampl M; Wentzensen N; Vinokurova S; von Knebel-Doeberitz M; Poremba C; Bender HG; Kueppers V
    J Cancer Res Clin Oncol; 2007 Apr; 133(4):235-45. PubMed ID: 17294241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.
    Garland SM; Joura EA; Ault KA; Bosch FX; Brown DR; Castellsagué X; Ferenczy A; Ferris DG; Giuliano AR; Hernandez-Avila M; Huh WK; Iversen OE; Kjaer SK; Kurman RJ; Luna J; Monsonego J; Muñoz N; Paavonen J; Pitisuttihum P; Ronnett BM; Steben M; Stoler MH; Wheeler CM; Wiley DJ; Perez G; Saah AJ; Luxembourg A; Li S; DiNubile MJ; Wagner M; Velicer C
    Obstet Gynecol; 2018 Aug; 132(2):261-270. PubMed ID: 29995724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.
    De Vuyst H; Clifford GM; Nascimento MC; Madeleine MM; Franceschi S
    Int J Cancer; 2009 Apr; 124(7):1626-36. PubMed ID: 19115209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer.
    Hampl M; Sarajuuri H; Wentzensen N; Bender HG; Kueppers V
    Obstet Gynecol; 2006 Dec; 108(6):1361-8. PubMed ID: 17138767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
    Mpunga T; Chantal Umulisa M; Tenet V; Rugwizangoga B; Milner DA; Munyanshongore C; Heideman DAM; Bleeker MCG; Tommasino M; Franceschi S; Baussano I; Gheit T; Sayinzoga F; Clifford GM
    Int J Cancer; 2020 Mar; 146(6):1514-1522. PubMed ID: 31173641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nine-valent HPV vaccine - new generation of HPV vaccine].
    Fait T; Dvořák V; Pilka R
    Ceska Gynekol; 2015 Dec; 80(6):397-400. PubMed ID: 26741152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Joura EA; Leodolter S; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Garland SM; Harper DM; Tang GW; Ferris DG; Steben M; Jones RW; Bryan J; Taddeo FJ; Bautista OM; Esser MT; Sings HL; Nelson M; Boslego JW; Sattler C; Barr E; Paavonen J
    Lancet; 2007 May; 369(9574):1693-702. PubMed ID: 17512854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.
    Hariri S; Unger ER; Schafer S; Niccolai LM; Park IU; Bloch KC; Bennett NM; Steinau M; Johnson ML; Markowitz LE;
    Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):393-9. PubMed ID: 25416715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus.
    Nicolás-Párraga S; Gandini C; Pimenoff VN; Alemany L; de Sanjosé S; Xavier Bosch F; Bravo IG;
    Cancer Med; 2016 Oct; 5(10):2909-2919. PubMed ID: 27654117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
    Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.
    Forcier M; Musacchio N
    Dermatol Ther; 2010; 23(5):458-76. PubMed ID: 20868401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HR-HPV E6/E7 mRNA In Situ Hybridization: Validation Against PCR, DNA In Situ Hybridization, and p16 Immunohistochemistry in 102 Samples of Cervical, Vulvar, Anal, and Head and Neck Neoplasia.
    Mills AM; Dirks DC; Poulter MD; Mills SE; Stoler MH
    Am J Surg Pathol; 2017 May; 41(5):607-615. PubMed ID: 28403015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancers attributable to human papillomavirus infection.
    Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
    Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.